Achillion (ACHN), Vertex (VRTX) Flying On Gilead's (GILD) '7977 Setback

February 17, 2012 9:13 AM EST Send to a Friend
Get Alerts VRTX Hot Sheet
Price: $108.16 +3.24%

Rating Summary:
    22 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 40
Trade VRTX Now!
Join SI Premium – FREE
Vertex Pharmaceuticals (Nasdaq: VRTX) is up 10 percent and Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is surging over 20 percent in pre-open trading Friday following a major setback for Gilead Sciences (Nasdaq: GILD) Hep C treatment '7977.

The news is seen as a positive for both, as analysts at Baird explains "The derivative from this update is positive for VRTX, because on the margin it could/should extend Incivek's tail, and for ACHN, because its assets are complementary to nukes, nukes may need help in at least some populations, and uncertainty in the field is good for ACHN."


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Momentum Movers, Trader Talk

Related Entities

Robert W Baird

Add Your Comment